Follow CAP on Social Media

Listen to the CAP Podcast

Why One Chinese COVID-19 Vaccine, in Particular, is Poised to Have a Huge Impact in the Developing World

Image of CanSino Biologics Inc. COVID019 vaccines that only require a single shot and less onerous cold chain requirements than other vaccines on the market. Image via CanSino.

A new Chinese-made vaccine emerged from late-stage clinical trials this week, well-positioned to help overcome a number of the obstacles that have hampered large-scale distribution of COVID-19 jabs to the world’s poorest countries, including many in Africa.

Monday’s announcement by Pakistani health advisor Faisal Sultan that CanSino Biologics’ vaccine emerged from late-stage clinical trials with a 65.7% efficacy rate. That by itself is encouraging, given that it’s far above the 50% rate required by the WHO for certification. But more importantly, the CanBio jab has a number of features that make it especially appealing for developing countries:

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Africa Project?


The CAP is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Africa stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalist and a variety of stakeholders in the China-Africa discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.